Results 71 to 80 of about 5,953 (226)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

Infection and Drug Resistance, 2019
Lindsey M Childs-Kean, Natalie A Brumwell, Emma F LodlDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAAbstract: The treatment of chronic hepatitis C has been revolutionized with the
Childs-Kean LM, Brumwell NA, Lodl EF
doaj  

High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4 [PDF]

, 2017
[Abstract] Background and Aims. Hepatitis C (HCV) therapy with Sofosbuvir (SOF)/Simeprevir (SMV) in clinical trials and real‐world clinical practice, showed high rates of sustained virological response (SVR) in non‐cirrhotic genotype (GT)‐1 and GT‐4 ...
Arencibia, Ana C., Artaza, Tomás de, Baliellas, Carme, Blasco, Alejandro, Cabezas, Joaquín, Calleja, José L., Carrión, José A., Castellote, José, Castells, Lluis, Castro-Iglesias, Ángeles, Crespo, Javier, Cuervas-Mons Martínez, Valentín, Diago, Moisés, Fernández, Inmaculada, Forns, Xavier, Forné, Monserrat, Gallego, Adolfo, García-Samaniego, Javier, Gea-Rodríguez, Francisco, Giráldez, Álvaro, Gómez, Alexandra, Hontangas, Vanessa, López-Núñez, Carmen, Mariño, Zoe, Montero, José L., Moreno, José M., Morillas, Rosa, Narváez, Isidro, Pascasio-Acevedo, Juan M., Pascual, Sonia, Prieto, Martín, Romero-Gómez, Manuel, Sánchez Ruano, Juan José, Sánchez-Antolín, Gloria, Torras, Xavier, Turnes, Juan, Vergara, Mercedes   +36 more
core   +2 more sources

Predictive Value of Sustained Virologic Response at Week 4 in Patients with Hepatitis C Virus Infection Treated with Sofosbuvir/Velpatasvir [PDF]

Viruses
Landry G, Sulkowski M, Feld J, Reau N, Scherbakovsky S, Black F, Hernández C, Mercier R, Ni L, Bourlière M, Mangia A.   +10 more
europepmc   +3 more sources

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study

Infectious Diseases and Therapy, 2020
Introduction Clinical trials of direct-acting antivirals for patients with decompensated cirrhosis have been conducted, but there is limited information on the medicinal applications in clinical settings.
Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Makoto Nakamuta, Koichi Takaguchi, Tsunamasa Watanabe, Atsushi Hiraoka, Haruki Uojima, Toru Ishikawa, Motoh Iwasa, Toshifumi Tada, Akito Nozaki, Makoto Chuma, Shinya Fukunishi, Akira Asai, Toru Asano, Chikara Ogawa, Hiroshi Abe, Naoki Hotta, Toshihide Shima, Etsuko Iio, Shigeru Mikami, Yoshihiko Tachi, Shinichi Fujioka, Hironao Okubo, Noritomo Shimada, Joji Tani, Isao Hidaka, Akio Moriya, Kunihiko Tsuji, Takehiro Akahane, Naoki Yamashita, Tomomi Okubo, Taeang Arai, Kiyoshi Morita, Kazuhito Kawata, Yasuhito Tanaka, Takeshi Okanoue, Shin Maeda, Takashi Kumada, Katsuhiko Iwakiri, KTK49 Liver Study Group   +42 more
doaj   +1 more source

Evolución de los pacientes infectados por el virus de la hepatitis C tratados con antivirales de acción directa en Álava. Durante el período 2015-2017. [PDF]

, 2018
[ES] La infección por el virus de la hepatitis C (VHC) en la población general se caracteriza por una evolución crónica y, en general, benigna, tal como demuestran los estudios epidemiológicos prospectivos y retrospectivos.
Gil González, Cristina
core  

HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype [PDF]

, 2019
The efficacy of licensed direct-acting antiviral (DAA) regimens is assumed to be the same for hepatitis C virus (HCV)–monoinfected patients (HCV-Mono) and HIV/HCV-coinfected patients (HCV-Co). However, the high sustained viral response (SVR) rates of DAA
Albillos, Agustín, Aldámiz-Echevarría, Teresa, Barrio, José, Bañares, Rafael, Benítez, Laura, Berenguer, Juan, Buey, Luisa García, Calleja, José Luis, Calvo, María J., Devesa, María J., Domínguez, Lourdes, Fernández, Inmaculada, Fernández-Rodríguez, Conrado, García-Samaniego, Javier, Gil, Ángela, González-García, Juan, Jarrín, Inmaculada, Losa, Juan E., Montes, María Luisa, Moreno, Ana, Olveira, Antonio, Polo, Benjamín A., Poves, Elvira, Ryan, Pablo, Santos, Ignacio, Sanz, José, Téllez, María Jesús, Álvarez, Beatriz   +27 more
core   +2 more sources

Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment : analysis of 5552 patients from 12 cohorts [PDF]

, 2020
Background and aims: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible.
Borgia S. M., Brown R. S., Carrat F., Doucette K., Fagiuoli S., Khalili M., Lampertico P., Losappio R., Mangia A., Mertens M., Milligan S., Ntalla I., Ouzan D., Papatheodoridis G., Perez-Hernandez F., Ramji A., Ramroth H., Shafran S. D., Turnes J., Vanstraelen K., Wedemeyer H., Wick N.   +21 more
core   +1 more source

High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam

Journal of Viral Hepatitis, Volume 32, Issue 11, November 2025.
ABSTRACT People who inject drugs (PWID) are highly affected by hepatitis C (HCV) worldwide, particularly in low‐ and middle‐income countries (LMICs), where access to addiction services is often limited. Reducing the burden of HCV, as promoted by WHO, requires effective interventions in this high‐risk population.
Didier Laureillard, Nguyen Thanh Binh, Vu Hai Vinh, Tran Thi Hong, Catherine Quillet, Nham Thi Tuyet Thanh, Roselyne Vallo, Bach Thi Nhu Quynh, Jean Pierre Moles, Khuat Thi Hai Oanh, Duong Thi Huong, Delphine Rapoud, Jonathan Feelemyer, Laurent Michel, Peter Vickerman, Hannah Fraser, Laurence Weiss, Maud Lemoine, Karine Lacombe, Don Des Jarlais, Pham Minh Khue, Nicolas Nagot   +21 more
wiley   +1 more source

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. [PDF]

, 2016
Background & Aims: Life expectancy of patients with compensated hepatitis C virus (HCV) cirrhosis achieving sustained virologic response (SVR) is limited by liver events as compared to the general population. Thus, survival benefit of SVR remains to
Aghemo A, Boccaccio V, Bruno S, Cabibbo G, Calvaruso V, Colombo M, Craxí A, Crosignani A, Di Marco V, Iavarone M, Maisonneuve P, Roffi L, Viganò M   +12 more
core   +1 more source

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir retreatment in hepatitis C patients with different genotypes with DAAs failure in East China [PDF]

, 2022
Shanshan Chen, Ke Zhou, Qiao Yang, Chunlian Ma, Jin Qian, Airong Hu, Jie Jin, Yan Dong, Fangfang Lv, Yongming Shi, Jie Yang, Fangqin Hu, Li Ma, Yunhao Xun, Haijun Huang   +14 more
openalex   +1 more source